BiomX PHGE
NYSE PHGE
$1.71 +0.09 (+5.56%)
As of: Sep 10, 2026 · 10:45 AM EDT

BiomX (PHGE) Notes Payables (2018 - 2026)

BiomX's (PHGE) quarterly Notes Payables came in at $1.3 million in Q2 2026, little changed quarter-over-quarter from $1.3 million in Q1 2026.

Analysis

BiomX (PHGE) Notes Payables (2018 - 2026) Analysis & Trends

BiomX has disclosed Notes Payables across 3 years of filings, most recently posting $1.3 million for Q2 2026.

  • In Q2 2026, Notes Payables changed N/A year-over-year to $1.3 million; the TTM figure through Jun 2026 stood at $1.3 million (changed N/A YoY), while the FY2019 annual figure was $375000.0, up 650.0% from the prior year.
  • Notes Payables came in at $1.3 million for Q2 2026 at BiomX, roughly flat from $1.3 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $1.3 million in Q1 2026 to a low of $1.3 million in Q1 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 207.59 Bn 193.60 Bn 7.24 Bn
2 Gilead Sciences 178.73 Bn 175.55 Bn 6.22 Bn
3 Vertex Pharmaceuticals 131.17 Bn 123.32 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 81.73 Bn 73.73 Bn 3.93 Bn
5 Argenx Se 61.01 Bn 55.82 Bn 1.37 Bn
6 Moderna 53.40 Bn 48.27 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.49 Bn 30.18 Bn 992.69 Mn
8 Biogen 31.64 Bn 30.35 Bn 1.96 Bn
9 Roivant Sciences 29.66 Bn 29.66 Bn 1.16 Mn
10 BiomX 17.64 Mn 17.06 Mn 97,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.25 Mn
Mar 31, 2026 1.25 Mn
Dec 31, 2019 375,000.00
Dec 31, 2018 50,000.00
Jun 30, 2018 40,000.00